Media headlines about Baxter International (NYSE:BAX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Baxter International earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the medical instruments supplier an impact score of 46.6855003400927 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
- Baxter Issues Recall of Nexterone Injection – ModernMedicine (drugtopics.modernmedicine.com)
- Global Biological Drugs Market 2017 – Amgen Inc., Baxter International Inc., Eli Lilly and Co., Merck & Co. – Medgadget (blog) (medgadget.com)
- $2.76 Billion in Sales Expected for Baxter International Inc. (BAX) This Quarter (americanbankingnews.com)
- BAXTER INTERNATIONAL : Presents Data on the Role of SHARESOURCE Telehealth Platform in Helping the Clinical Management of Peritoneal Dialysis Patients (4-traders.com)
- Trump Focuses on APAC: 4 MedTech Stocks to Watch (finance.yahoo.com)
Shares of Baxter International (BAX) opened at $64.55 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.80 and a quick ratio of 2.22. The company has a market capitalization of $35,098.07, a PE ratio of 26.62, a P/E/G ratio of 2.16 and a beta of 0.68. Baxter International has a 52-week low of $43.13 and a 52-week high of $65.70.
Baxter International (NYSE:BAX) last posted its earnings results on Wednesday, October 25th. The medical instruments supplier reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.05. The company had revenue of $2.71 billion for the quarter, compared to the consensus estimate of $2.66 billion. Baxter International had a return on equity of 15.00% and a net margin of 9.88%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.56 earnings per share. analysts anticipate that Baxter International will post 2.43 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, January 2nd. Shareholders of record on Friday, December 1st will be given a dividend of $0.16 per share. The ex-dividend date of this dividend is Thursday, November 30th. This represents a $0.64 dividend on an annualized basis and a yield of 0.99%. Baxter International’s dividend payout ratio (DPR) is presently 34.41%.
A number of research analysts have issued reports on the company. Stifel Nicolaus reiterated a “hold” rating and set a $65.00 price objective on shares of Baxter International in a research note on Thursday, October 26th. Barclays PLC lifted their price objective on Baxter International from $70.00 to $73.00 and gave the stock an “overweight” rating in a report on Thursday, October 26th. Morgan Stanley lifted their price objective on Baxter International from $59.00 to $62.00 and gave the stock an “equal weight” rating in a report on Thursday, October 26th. Zacks Investment Research raised Baxter International from a “hold” rating to a “buy” rating and set a $72.00 price objective for the company in a report on Tuesday, October 24th. Finally, Royal Bank Of Canada reaffirmed a “hold” rating and issued a $60.00 price objective on shares of Baxter International in a report on Tuesday, October 3rd. Six research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $67.00.
In other news, Director Carole J. Shapazian sold 4,020 shares of the stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $61.61, for a total value of $247,672.20. Following the sale, the director now directly owns 13,868 shares in the company, valued at $854,407.48. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Third Point Llc sold 5,000,000 shares of the stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $64.23, for a total value of $321,150,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,022,380 shares of company stock worth $322,536,224. Company insiders own 0.05% of the company’s stock.
About Baxter International
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.